Antibody changes in paragonimiasis patients after praziquantel treatment as observed by ELISA and immunoblot

, Cho, S Y; , Kim, S I; , Kang, S Y; , Kong, Y; , Han, S K; , Shim, Y S; , Han, Y C

doi:1989.27.1.15

Korean J Parasito > Volume 27(1):1989 > Article

Original Article


Korean J Parasitol. 1989 Mar;27(1):15-21. English. Published online Mar 20, 1994. http://dx.doi.org/10.3347/kjp.1989.27.1.15
Copyright © 1989 by The Korean Society for Parasitology


Antibody changes in paragonimiasis patients after praziquantel treatment as observed by ELISA and immunoblot
S Y Cho,S I Kim,S Y Kang,Y Kong,S K Han,^Y S Shim,^ and Y C Han^*
Department of Parasitology, College of Medicine, Chung-Ang University, Seoul 156-756, Korea.
Department of Internal Medicine^*, Seoul National University Hospital, Seoul 110-744, Korea.


Abstract
To observe antibody changes after praziquantel treatment in paragonimiasis, a total of 46 serum samples from 13 serologically diagnosed patients was collected for 4-28 months. The specific antibody (IgG) levels were measured by enzyme-linked immunosorbent assay (ELISA). All but one patient who needed retreatment became symptom-free within a week. Antibody levels were dropped near to or below a cut-off absorbance (abs.) of 0.25 in varying intervals from 4 to 18 months. Of 9 patients who were retested within 3 months, 5 revealed temporary elevation of antibody level. After the elevation, the levels began to decline slowly to negative ranges. If treated earlier after symptoms developed, the temporary elevation did not occur and intervals to negative conversion were shorter. By sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)/immunoblot, antigen-antibody reactions in individual patient faded gradually without significant changes in reacting antigen bands.

Figures


	Fig. 1 Absorbance changes before and after praziquantel treatment in paragonimiasis patients by ELISA. A-M : Patient number. Dotted band at abs. 0.25 : Criterion of positive reaction (Bf : Before the praziquantel treatment. ↓ : Praziquantel treatment).


	Fig. 2 SDS-PAGE/immunoblot of paragonimiasis patients before and after praziquantel treatment. Saline extract of adult P. westermani was electrophoresed in reducing condition. A-M : Patients number. B, 0~28 at top of immunoblot: B: before treatment 0 : At the time of treatment, 1~28 : Months after the treatment. Numerals standing at left column: Molecular weight in kDa.

Tables


	Table 1 Symptoms and duration of illness in the subjected patients

References


1.	Cho SY, Hong ST, Rho YH, Choi SY, Han YC. Application of micro-ELISA in serodiagnosis of Human paragonimiasis. Korean J Parasitol 1981;19(2):151–156.

2.	Cho SY, Lee DK, Kang SY, Kim SI. [An Epidemiological Study Of Human Paragonimiasis By Means Of Micro-ELISA]. Korean J Parasitol 1983;21(2):246–256.

3.	Choi WY, Yoo JE, Nam HW, Choi HR. [Purification of antigenic proteins of Paragonimus westermani and their applicability to experimental cat paragonimiasis]. Korean J Parasitol 1986;24(2):177–186.

4.	Imai J. Evaluation of ELISA for the diagnosis of paragonimiasis westermani. Trans R Soc Trop Med Hyg 1987;81(1):3–6.

5.	Itoh M, Sato S. Jpn J Parasitol 1988;37:347–352.

6.	Kim SH, Kong Y, Kim SI, Kang SY, Cho SY. Immunoblot observation of antigenic protein fractions in Paragonimus westermani reacting with human patients sera. Korean J Parasitol 1988;26(4):239–243.

7.	Kim SI, Ko EK, Kang SY, Cho SY. [Antigenicity of the soluble egg antigen of Paragonimus westermani]. Korean J Parasitol 1986;24(1):49–54.

8.	Knobloch J, Lederer I. Immunodiagnosis of human paragonimiasis by an enzyme immunoassay. Tropenmed Parasitol 1983;34(1):21–23.

9.	Knobloch J, Paz G, Feldmeier H, Wegner D, Voelker J. Serum antibody levels in human paragonimiasis before and after therapy with praziquantel. Trans R Soc Trop Med Hyg 1984;78(6):835–836.

*10.*	Kojima S, et al. Jpn J Parasitol 1983;32:413–418.

*11.*	Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5259):680–685.

*12.*	Lee OR, Choi WY. [Comparison Of Agar-Gel Diffusion Tests, Counterimmunoelectrophoresis And Enzyme-Linked Immunosorbent Assay In The Sera Of Skin Test Positives For Paragonimiasis]. Korean J Parasitol 1983;21(2):270–280.

*13.*	Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193(1):265–275.

*14.*	Rim HJ, Chang YS, Lee JS, Joo KH, Suh WH, Tsuji M. Clinical Evaluation Of Praziquantel(Embay 8440; Biltricide(R)) In The Treatment Of Paragonimus Westermani. Korean J Parasitol 1981;19(1):27–37.

*15.*	Slemenda SB, Maddison SE, Jong EC, Moore DD. Diagnosis of paragonimiasis by immunoblot. Am J Trop Med Hyg 1988;39(5):469–471.

*16.*	Sugiyama H, Sugimoto M, Akasaka K, Horiuchi T, Tomimura T, Kozaki S. Characterization and localization of Paragonimus westermani antigen stimulating antibody formation in both the infected cat and rat. J Parasitol 1987;73(2):363–367.

*17.*	Tsang VC, Peralta JM, Simons AR. Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis. Methods Enzymol 1983;92:377–391.

*18.*	Tsuji M. Pre- and posttreatment serodiagnosis for paragonimiasis. Arzneimittelforschung 1984;34(9B):1204–1207.

*19.*	Yokogawa M. Paragonimus and paragonimiasis. Adv Parasitol 1965;3:99–158.

*20.*	Yokogawa M, et al. Jpn J Parasitol 1983;32:317–322.